Simulations Plus Presented New Scientific Developments at PAGE 2022

Several posters and oral presentations involved the use of MonolixSuite®

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five scientific posters by Simulations Plus scientists at the Population Approach Group in Europe (PAGE) conference held in Ljubljana, Slovenia from June 28 to July 1, 2022.

Since 1992, the PAGE conference has brought together a scientific community with a shared interest in data analysis using the population approach. This year’s meeting took place in an informal setting where more than 600 scientists gathered to engage in vibrant scientific discussions.

Dr. Jonathan Chauvin, President of the Lixoft division at Simulations Plus, said: “After a two-year hiatus, we were eager to attend this face-to-face meeting, and Simulations Plus products and services were well represented. PAGE meetings always generate productive discussions – beginning with our vision of how our products and services can greatly improve modeling and simulation efforts to the valuable feedback we get from our user community.”

Chauvin continued: “Key thought leaders in the community presented new scientific developments that are now included in the MonolixSuite platform, such as the work presented by Prof. Marc Lavielle: ‘SAMBA: a new algorithm for automatic construction of nonlinear mixed-effects models.’ Moreover, MonolixSuite was used for the Nonlinear Mixed Effect (NLME) modeling in the work presented by Dr. Sébastien Benzekry: ‘Supporting decision making and early prediction of survival for oncology drug development using a pharmacometrics-machine learning based model.’ As a result of this dynamic, collaborative atmosphere, we have seen a substantial increase in the adoption of MonolixSuite.”

About Simulations Plus

Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.


Simulations Plus Investor Relations
Ms. Renee Bouche


Hayden IR
Mr. Brian Siegel


error: Content is protected !!